Phaseline

Companies › Shandong New Time Pharmaceutical

Shandong New Time Pharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 40 registered trials: 24 Phase 2, 14 Phase 1, 2 Phase 3; Immunology, Oncology, Neurology, Infectious disease; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pomalidomide (F182112)
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Relapsed or Refractory Multiple Myeloma (RRMM); Relapsed or Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE); Multiple Myeloma …Dec 2027
Cetirizine
Histamine H1 receptor antagonist
HRH1Phase 3Acute Urticaria–
F520–Phase 2Cancer of Unknown Primary SiteDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04667663Pomalidomide (F182112)Phase 1Multiple MyelomaOncologyApr 2022
NCT02406222Pomalidomide (F182112)Phase 2Multiple MyelomaOncologyDec 2022
NCT03756896Pomalidomide (F182112)Phase 2Plasma Cell MyelomaOncologyJun 2025
NCT06819774CetirizinePhase 3Acute UrticariaImmunologyAug 2025
NCT06158412Pomalidomide (F182112)Phase 2Multiple Myeloma in RelapseOncologyDec 2025
NCT04902443Pomalidomide (F182112)Phase 1Viral Associated MalignanciesOncologyDec 2026
NCT06342466Pomalidomide (F182112)Phase 2Systemic AmyloidosisMetabolic and endocrineDec 2026
NCT06855823Pomalidomide (F182112)Phase 1Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)OncologyDec 2026
NCT04883242Pomalidomide (F182112)Phase 2Recurrent Multiple MyelomaOncologyDec 2026
NCT04094961Pomalidomide (F182112)Phase 1Multiple MyelomaOncologyJan 2027
NCT04270175Pomalidomide (F182112)Phase 2AmyloidNeurologyJan 2027
NCT04577755Pomalidomide (F182112)Phase 2Skin Kaposi SarcomaOncologyFeb 2027
NCT04508790Pomalidomide (F182112)Phase 2Recurrent Plasma Cell MyelomaOncologyFeb 2027
NCT06660498Pomalidomide (F182112)Phase 1HIV-1 InfectionInfectious diseaseMar 2027
NCT04835129Pomalidomide (F182112)Phase 2Multiple MyelomaOncologyApr 2027
NCT04802161Pomalidomide (F182112)Phase 2Acute Myeloid LeukemiaOncologyApr 2027
NCT03715478Pomalidomide (F182112)Phase 1Relapsed and/or Refractory Multiple MyelomaOncologyJun 2027
NCT04124497Pomalidomide (F182112)Phase 2Multiple MyelomaOncologyJul 2027
NCT07532525Pomalidomide (F182112)Phase 1Recurrent B Acute Lymphoblastic LeukemiaOncologyAug 2027
NCT04790474Pomalidomide (F182112)Phase 2Multiple Myeloma in RelapseOncologySep 2027
NCT03030261Pomalidomide (F182112)Phase 2Multiple Myeloma in RelapseOncologySep 2027
NCT04850599Pomalidomide (F182112)Phase 2Recurrent Plasma Cell MyelomaOncologyOct 2027
NCT05556798Pomalidomide (F182112)Phase 1Multiple MyelomaOncologyOct 2027
NCT05208307Pomalidomide (F182112)Phase 2Plasma Cell MyelomaOncologyOct 2027
NCT04764942Pomalidomide (F182112)Phase 1Recurrent Multiple MyelomaOncologyDec 2027
NCT04302324Pomalidomide (F182112)Phase 2Multiple MyelomaOncologyDec 2027
NCT07761429F520Phase 2Cancer of Unknown Primary SiteOncologyDec 2027
NCT07829614Pomalidomide (F182112)Phase 1Systemic Lupus Erythematosus (SLE)ImmunologyDec 2027
NCT02659930Pomalidomide (F182112)Phase 1Kaposi SarcomaOncologyJan 2028
NCT06879379Pomalidomide (F182112)Phase 2Multiple Myeloma, Newly DiagnosedOncologyMar 2028
NCT05911321Pomalidomide (F182112)Phase 2Multiple MyelomaOncologyMar 2028
NCT07523737Pomalidomide (F182112)Phase 2Primary Central Nervous System Lymphoma (PCNSL)OncologyMar 2028
NCT07312188Pomalidomide (F182112)Phase 2Relapsed or Refractory Multiple MyelomaOncologyMay 2028
NCT07312188Pomalidomide (F182112)Phase 2Relapsed or Refractory Multiple MyelomaOncologyMay 2028
NCT07312188Pomalidomide (F182112)Phase 2Relapsed or Refractory Multiple MyelomaOncologyMay 2028
NCT05389423Pomalidomide (F182112)Phase 1Diffuse Large Cell LymphomaOncologyJun 2028
NCT07579234Pomalidomide (F182112)Phase 3Relapsed or Refractory Multiple Myeloma (RRMM)OncologyJan 2029
NCT07463807Pomalidomide (F182112)Phase 1Recurrent Multiple MyelomaOncologyMar 2029
NCT06554561Pomalidomide (F182112)Phase 1PCNSLOncologyAug 2029
NCT07749365Pomalidomide (F182112)Phase 2DLBCL - Diffuse Large B Cell LymphomaOncologyDec 2029

Targets

HRH1 (1) CRBN (1) DDB1 (1) CUL4A (1) RBX1 (1)

Companies with the same targets

Bristol-Myers Squibb Roche Incyte Beijing InnoCare Pharma Tech CellCentric Noucor Health

Companies built like this

CellCentric Saol Therapeutics Shanghai Ming Ju Biotechnology Innovent Biopharmaceutical Technology (Hangzhou) Industrial Farmacéutica Cantabria

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.